22.69
4.85%
1.05
Arvinas Inc stock is traded at $22.69, with a volume of 729.87K.
It is up +4.85% in the last 24 hours and down -16.30% over the past month.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
See More
Previous Close:
$21.64
Open:
$21.59
24h Volume:
729.87K
Relative Volume:
1.33
Market Cap:
$1.56B
Revenue:
$71.30M
Net Income/Loss:
$-354.80M
P/E Ratio:
-4.059
EPS:
-5.59
Net Cash Flow:
$-356.00M
1W Performance:
-10.46%
1M Performance:
-16.30%
6M Performance:
-31.78%
1Y Performance:
+4.23%
Arvinas Inc Stock (ARVN) Company Profile
Name
Arvinas Inc
Sector
Industry
Phone
203-535-1456
Address
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
ARVN | 22.69 | 1.56B | 71.30M | -354.80M | -356.00M | -5.59 |
VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-14-24 | Downgrade | Citigroup | Buy → Neutral |
Feb-01-24 | Initiated | Goldman | Buy |
Dec-19-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Dec-06-23 | Upgrade | Jefferies | Hold → Buy |
Nov-20-23 | Upgrade | Guggenheim | Neutral → Buy |
Oct-23-23 | Upgrade | Wedbush | Neutral → Outperform |
Jun-26-23 | Resumed | Oppenheimer | Outperform |
Jan-12-23 | Downgrade | Guggenheim | Buy → Neutral |
Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Sep-09-22 | Initiated | Barclays | Overweight |
Jun-21-22 | Initiated | Jefferies | Hold |
May-09-22 | Downgrade | Wedbush | Outperform → Neutral |
Apr-28-22 | Initiated | Credit Suisse | Outperform |
Apr-06-22 | Initiated | Morgan Stanley | Equal-Weight |
Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
Feb-10-22 | Initiated | Wells Fargo | Overweight |
Jan-19-22 | Initiated | Goldman | Buy |
Dec-07-21 | Initiated | Cowen | Outperform |
Oct-14-21 | Initiated | SVB Leerink | Outperform |
Sep-30-21 | Initiated | Stifel | Buy |
Sep-09-21 | Initiated | BofA Securities | Buy |
May-21-21 | Initiated | UBS | Buy |
Apr-21-21 | Initiated | Truist | Buy |
Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
Dec-14-20 | Upgrade | Oppenheimer | Perform → Outperform |
Jun-01-20 | Upgrade | Citigroup | Neutral → Buy |
May-12-20 | Initiated | Oppenheimer | Perform |
Dec-19-19 | Initiated | H.C. Wainwright | Buy |
Nov-25-19 | Initiated | Guggenheim | Buy |
Oct-24-19 | Upgrade | Goldman | Neutral → Buy |
Sep-25-19 | Initiated | Wedbush | Outperform |
Sep-12-19 | Initiated | BMO Capital Markets | Outperform |
Aug-06-19 | Initiated | Cantor Fitzgerald | Overweight |
Jun-05-19 | Downgrade | Citigroup | Buy → Neutral |
Apr-12-19 | Initiated | Evercore ISI | Outperform |
Oct-22-18 | Initiated | Citigroup | Buy |
Oct-22-18 | Initiated | Goldman | Neutral |
Oct-22-18 | Initiated | Piper Jaffray | Overweight |
View All
Arvinas Inc Stock (ARVN) Latest News
Arvinas stock remains a Top Pick despite slight reduction in price target, says BMO - Investing.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Stockholders to Reach Out - AccessWire
Unveiling 4 Analyst Insights On Arvinas - Benzinga
Arvinas shares target cut to $62 on delayed trial data - Investing.com
Arvinas reports delay in breast cancer trial results - Investing.com India
Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode - Insider Monkey
Pfizer, Arvinas delay late-stage trial for breast cancer therapy - Seeking Alpha
Stephens Begins Coverage on Arvinas (NASDAQ:ARVN) - MarketBeat
Short Interest in Arvinas, Inc. (NASDAQ:ARVN) Drops By 5.6% - MarketBeat
Stephens & Co. Initiates Coverage of Arvinas (ARVN) with Overweight Recommendation - MSN
RTW INVESTMENTS, LP Adjusts Stake in Arvinas Inc - GuruFocus.com
Arvinas chief accounting officer David Loomis sells $10,300 in stock By Investing.com - Investing.com Australia
Arvinas chief accounting officer David Loomis sells $10,300 in stock - Investing.com
How the (ARVN) price action is used to our Advantage - Stock Traders Daily
Arvinas, Inc. (NASDAQ:ARVN) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Arvinas, Inc. (NASDAQ:ARVN) Receives $56.92 Consensus Target Price from Analysts - MarketBeat
Arvinas (ARVN) Stock Price, News & Analysis - MarketBeat
Arvinas's SWOT analysis: biotech stock poised for pivotal trial results - Investing.com India
Arvinas's SWOT analysis: biotech stock poised for pivotal trial results By Investing.com - Investing.com Canada
Allspring Global Investments Holdings LLC Has $182,000 Stake in Arvinas, Inc. (NASDAQ:ARVN) - Defense World
Arvinas to Participate in Upcoming Investor Conferences - GlobeNewswire
Arvinas (NASDAQ:ARVN) Receives Buy Rating from HC Wainwright - Defense World
FY2024 EPS Estimates for Arvinas Reduced by Leerink Partnrs - MarketBeat
Wedbush Issues Pessimistic Estimate for Arvinas Earnings - Defense World
FY2024 EPS Estimates for Arvinas Cut by Leerink Partnrs - Defense World
Arvinas (NASDAQ:ARVN) Price Target Lowered to $40.00 at Oppenheimer - Defense World
Arvinas Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Oppenheimer cuts Arvinas shares price target to $40 ahead of TACTIVE-U trial - Investing.com
Arvinas' (ARVN) Buy Rating Reiterated at HC Wainwright - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Q3 2024 Earnings Call Transcript - Insider Monkey
Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates - MSN
Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Reve - GuruFocus.com
Assenagon Asset Management S.A. Invests $3.44 Million in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Promising ... - Yahoo Finance
Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Promising ... By GuruFocus - Investing.com Canada
Arvinas Reports Progress in Q3 2024 Financials and Trials - TipRanks
Arvinas Inc (ARVN) Q3 2024 Earnings: Revenue Soars to $102.4M, B - GuruFocus.com
Arvinas (NASDAQ:ARVN) Trading 4.3% HigherTime to Buy? - MarketBeat
Arvinas earnings beat by $0.16, revenue topped estimates - Investing.com Canada
Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Arvinas, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Arvinas Inc (ARVN) Q3 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com
Arvinas, Inc. (NASDAQ:ARVN) Short Interest Down 12.7% in October - MarketBeat
We're Hopeful That Arvinas (NASDAQ:ARVN) Will Use Its Cash Wisely - Yahoo Finance
Arvinas (ARVN): A Small-Cap Biotech with High Growth Potential - Insider Monkey
Arvinas (ARVN) to Release Earnings on Wednesday - MarketBeat
8 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey
Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day - ForexTV.com
SG Americas Securities LLC Sells 76,236 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas Inc Stock (ARVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):